Property:Dosage and regime
This is a property of type Text.
U
Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study +
Daily dose 4x500mg before meals and one in the evening from day 1 to day 5 of chemotherapy
+ standard antiemetic medication included 20 mg of dexamethasone, 8 mg of ondansetron, and 50 mg of ranitidine which were injected 30 min before chemotherapy administration; if necessary 50mg dimenhydrinate before chemotherapy and 5 days at home +
Uthaipaisanwong et al. (2020): Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study +
Daily dose before meals and one in the evening from day 1 to day 5 of chemotherapy
+ standard antiemetic medication included 20 mg of dexamethasone, 8 mg of ondansetron, and 50 mg of ranitidine which were injected 30 min before chemotherapy administration; if necessary 50mg dimenhydrinate before chemotherapy and 5 days at home +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
Stimulation of the reflex points 20 min. of the right foot and 10 min. of the left foot, 2x/week, 5 weeks in total),
+ chemoradiantherapy +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
Chemoradiantherapy,
no information about duration in days +
Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial +
10 min per foot and dorsum, 2x/week, 5 weeks in total, + chemoradiantherapy, +
V
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
- Retinyl palmite (300 000 IU daily for 1 year followed by 150 000 IU for the 2nd year)
- N-acetylcysteine (600 mg daily for 2 years) +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
1st year: retinyl palmitate (300,000 IU) 1x/day
2nd year: retinyl palmitate (150,000 IU) 1x/day +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
600mg NAC 1x/day +
Van Zandwijk et al. (2000): EUROSCAN, a Randomized Trial of Vitamin A and N-Acetylcysteine in Patients With Head and Neck Cancer or Lung Cancer +
NA +
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial +
Oral, 400mg daily
Start: after randomization prior to chemotherapy
Duration: until 3 months post-CTX +
Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial +
Oral, 400mg daily
Start: after randomization prior to chemotherapy
Duration: until 3 months post-CTX +
3x5 tablets of WOBE-MUGOS (100mg papainases, 40mg trypsin, 40mg chymotrypsin, 40mg hydrolysate from calf thymus) daily 30 minutes before a meal
+ all patients: radiation therapy with a cumulative total radiation dose of approximately 50 Gy +
No additional intervention
+ all patients: radiation therapy with a cumulative total radiation dose of approximately 50 Gy +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
6 g/day of placebo in two daily doses of 3g +
Vitale et al. (2020): ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy +
6g/day in two doses of 3g at the start of chemotherapy +
W
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
NA +
Walsh et al. (2010): Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma +
4 μg of 1,25(OH)<sub>2</sub> D<sub></sub> for each of 3 sequential days, followed by 4 days of no treatment +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Orally rinsed with azulene solution (prepared by pouring 7 drops of 4% liquid solution into 100 ml water) for 3 min 4 times in a day;
Duration: from the start to the end of the radiotherapy +
Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer +
Orally rinsed with Polaprezinc solution (Polaprezinc granules (0.5g) were dissolved in 20 ml of 5% sodium alginate solution, a natural thickener used as food additive, by agitating intermittently for 1 hr) for 3 min 4 times in a day, the solution was swallowed after oral rinse;
Duration: from the start to the end of the radiotherapy +
Wrbka et al. (1987): Unterstützung der Chemotherapie inoperabler Karzinome durch proteolytische Fermente +
2x daily Wobe Mugos microclysms, 5g each, for 1 to 4 weeks (average 2 weeks) and further outpatient treatment with dragees
+ all patients: Poly-chemotherapy (Fluoro-Uracil, Vinblastin, Metothrexat, Cyclophosphamid) +